Multiple system atrophy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:25:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Multiple system atrophy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Open-Label Extension Study of ATH434-DP2 in Patients with Multiple System Atrophy https://clinicaltrials.eu/trial/ath434-dp2-in-patients-with-multiple-system-atrophy/ Tue, 02 Jun 2026 09:56:37 +0000 https://clinicaltrials.eu/trial/ath434-dp2-in-patients-with-multiple-system-atrophy/ This clinical trial is being done in Multiple System Atrophy, a rare disease that affects body movement, balance, and some automatic body functions such as blood pressure control. The study uses ATH434-DP2, a tablet taken by mouth, to provide continued access to this treatment and to look at its long-term safety and how well it is tolerated.

The purpose of the study is to assess the long-term safety and tolerability of ATH434-DP2 in people with Multiple System Atrophy. In this open-label extension study, treatment is given for an extended period, and participants continue taking the study medicine while the study team monitors general health, side effects, blood pressure changes when standing up, and other routine medical checks. The study is designed to follow how people do over time without using a placebo.

]]> A Study of Emrusolmin Safety and Effectiveness in Adults with Multiple System Atrophy, a Brain and Nerve Disorder https://clinicaltrials.eu/trial/a-study-of-emrusolmin-safety-and-effectiveness-in-adults-with-multiple-system-atrophy-a-brain-and-nerve-disorder/ Thu, 30 Apr 2026 13:08:36 +0000 https://clinicaltrials.eu/trial/a-study-of-emrusolmin-safety-and-effectiveness-in-adults-with-multiple-system-atrophy-a-brain-and-nerve-disorder/ This study involves people with Multiple System Atrophy, a rare condition that affects the nervous system and causes problems with movement, balance, and body functions such as blood pressure control and bladder function. The study will test a medicine called Emrusolmin, which is also known by its code name TEV-56286. This medicine comes in capsule form and is taken by mouth. The medicine is being tested to see if it can help treat people with this condition.

The main purpose of the study is to learn about the long-term safety of Emrusolmin and how well people tolerate taking it over an extended period of time. The study will look at whether people experience any unwanted effects from the medicine and whether they are able to continue taking it without problems. This is called an open-label extension study, which means it follows on from an earlier study and all people taking part will know they are receiving the actual medicine rather than a placebo.

People who join this study must have already completed an earlier study with this medicine and must be able to swallow the capsules whole. During the study, people will take Emrusolmin capsules regularly and will attend visits where doctors will check their health and watch for any side effects. The medicine will be taken daily with a maximum dose of 300 milligrams per day. The study will continue for up to 96 weeks to collect information about how safe the medicine is when used over a longer time period.

]]> Long-term safety and effectiveness follow-up study of AB-1005 gene therapy in patients with Parkinson’s disease or multiple system atrophy https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-follow-up-study-of-ab-1005-gene-therapy-in-patients-with-parkinsons-disease-or-multiple-system-atrophy/ Wed, 29 Apr 2026 15:08:35 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-follow-up-study-of-ab-1005-gene-therapy-in-patients-with-parkinsons-disease-or-multiple-system-atrophy/ This study involves people with Parkinson’s Disease or Multiple System Atrophy, which are conditions that affect movement and other body functions due to problems with certain brain cells. The study uses a treatment called AB-1005, which is a gene therapy designed to deliver a protective protein to specific areas of the brain. During the treatment procedure, Carbidopa tablets are given by mouth and Fluorodopa (18F) is given through a vein as an injection. AB-1005 is given as a single injection directly into a part of the brain called the putamen.

The purpose of this study is to learn more about the long-term safety and how well AB-1005 works in people with these movement disorders. This is a follow-up study for people who are currently taking part in or have previously taken part in another study testing AB-1005. The study will track participants over many years to watch for any side effects and to see how their symptoms change over time.

During the study, participants will have regular check-ups where doctors will look for any unwanted effects of the treatment and measure how well participants can move and perform daily activities. For people with Parkinson’s Disease, the study will track their motor symptoms, how much medication they need, and will use a special brain scan called 18F-DOPA PET to see how the brain is working. For people with Multiple System Atrophy, the study will measure movement abilities and quality of life using standard rating scales. The study will continue for several years to gather information about the long-term effects of this gene therapy treatment.

]]> Study of Amlenetug for Patients with Multiple System Atrophy https://clinicaltrials.eu/trial/study-of-amlenetug-for-patients-with-multiple-system-atrophy/ Wed, 29 Apr 2026 15:03:05 +0000 https://clinicaltrials.eu/trial/study-of-amlenetug-for-patients-with-multiple-system-atrophy/ This clinical trial is focused on studying a condition known as Multiple System Atrophy (MSA), a rare neurological disorder that affects the body’s involuntary functions, such as blood pressure, breathing, and motor control. The trial will investigate the effects of a treatment called Lu AF82422, also known as Amlenetug, which is a type of protein designed to target specific proteins in the brain. This treatment is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective Lu AF82422 is in slowing down the progression of MSA. Participants in the trial will receive either the treatment or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results. The trial will also include an optional open-label extension, where all participants may have the opportunity to receive the actual treatment after the initial phase.

Throughout the study, participants will be monitored for changes in their condition over a period of time, with assessments taking place up to 72 weeks. These assessments will include various tests and evaluations to measure the impact of the treatment on the symptoms and progression of MSA. The trial aims to provide valuable insights into the potential benefits of Lu AF82422 for individuals living with this challenging condition.

]]> Study on the Effects of TAK-341 for Patients with Multiple System Atrophy https://clinicaltrials.eu/trial/study-on-the-effects-of-tak-341-for-patients-with-multiple-system-atrophy/ Wed, 29 Apr 2026 14:59:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-tak-341-for-patients-with-multiple-system-atrophy/ This clinical trial is focused on studying a disease called Multiple System Atrophy (MSA). MSA is a rare condition that affects the nervous system, leading to problems with movement, balance, and the function of various body systems. The study is testing a treatment called TAK-341, which is a type of medication known as a human IgG1 lambda monoclonal antibody against alpha-synuclein. This medication is given through an infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective and safe TAK-341 is for people with MSA. Participants in the study will receive either the medication or a placebo, which is a substance with no active ingredients. The study will last for about 52 weeks, during which participants will have regular check-ups and assessments to monitor their health and the effects of the treatment. These assessments will include various tests and evaluations to see how the treatment is working and to ensure the safety of the participants.

Throughout the study, participants will be closely monitored by healthcare professionals. The study aims to provide valuable information about the potential benefits and safety of TAK-341 for treating Multiple System Atrophy. This research could help improve the understanding and management of this challenging condition in the future.

]]> Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-exidavnemab-in-patients-with-mild-to-moderate-parkinsons-disease/ Wed, 29 Apr 2026 14:59:12 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-exidavnemab-in-patients-with-mild-to-moderate-parkinsons-disease/ This clinical trial is focused on studying Parkinson’s Disease, a condition that affects movement and can cause symptoms like tremors, stiffness, and difficulty with balance and coordination. The trial will test a new treatment called Exidavnemab, which is a type of medication known as a monoclonal antibody. This medication is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein.

The purpose of the study is to evaluate the safety and tolerability of Exidavnemab in patients with mild to moderate Parkinson’s Disease who are already on stable medication for their symptoms. Participants in the study will receive either the new treatment or a placebo, which is a substance with no active medication. The study will involve multiple doses of the treatment over a period of time to observe any potential side effects and how well the treatment is tolerated by the participants.

Throughout the study, participants will be monitored for any changes in their health, including vital signs like blood pressure and heart rate, as well as laboratory tests. The study aims to gather information on the best dose of Exidavnemab and how it behaves in the body. This research is important for understanding if Exidavnemab could be a safe and effective treatment option for people living with Parkinson’s Disease.

]]> Study of Emrusolmin for Treating Adults with Multiple System Atrophy https://clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/ Wed, 29 Apr 2026 14:30:08 +0000 https://clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/ This clinical trial is focused on studying a condition known as Multiple System Atrophy (MSA), a rare neurological disorder that affects the body’s involuntary functions, such as blood pressure, breathing, and motor control. The study will evaluate a new treatment called Emrusolmin, which is also known by its code name TEV-56286. This medication is taken orally in the form of a capsule. The trial will compare the effects of Emrusolmin with a placebo to understand its effectiveness in treating MSA.

The purpose of the study is to assess how well Emrusolmin works in improving the symptoms of MSA. Participants in the study will be randomly assigned to receive either Emrusolmin or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are unbiased. The study will last for a period of 48 weeks, during which participants will be monitored regularly to track any changes in their condition and to ensure their safety.

Throughout the study, various assessments will be conducted to evaluate the impact of the treatment on the participants’ symptoms and overall quality of life. These assessments will include standardized tests and questionnaires that measure the severity of MSA symptoms and the participants’ well-being. The study aims to provide valuable information about the potential benefits of Emrusolmin for individuals living with Multiple System Atrophy.

]]>